Charles M. Beasley, Jr., M.D.
Publications – 29-December 2015

PATENTS ISSUED
5605897 2-Methyl-Thieno-Benzodiazepine (Olanzapine)
5817656 Method for Treating Mental Disorders (Olanzapine)
5817657 Method for Treating Psychoactive Substance Disorders (Olanzapine)
5776928 Method for Treating Dyskinesia (Olanzapine)
6071902 Method for Treating Excessive Aggression (Olanzapine)
6159963 Method for Treating Substance Abuse (Olanzapine)
6274636 Method of Treating Tic Disorder (Olanzapine)
6506746 Method for Treating Cognitive Dysfunction (Olanzapine)

BOOK CHAPTERS
   Overview of the safety of olanzapine
   In Tran P, Bymaster F, Tye N, Herrera J, Breier A, Tollefson G (Eds.)
   Olanzapine (Zyprexa): A Novel Antipsychotic
2. Tran P, Sutton V, Beasley C, Tollefson G
   Efficacy of olanzapine
   In Tran P, Bymaster F, Tye N, Herrera J, Breier A, Tollefson G (Eds.)
   Olanzapine (Zyprexa): A Novel Antipsychotic
3. Anderson J, Kline P, Beasley C
   A general learning theory and its application to schema abstraction
   In Bower G (Ed.)
4. Anderson J, Kline P, Beasley C
   Complex learning processes
   In Snow R, Federico P & Montague W (Eds.)
ARTICLES

1. Crowe B, Brueckner A, Beasley C, Kulkarni P
   **Current practices, challenges, and statistical issues with product safety labeling**

   **Effect of atomoxetine on the QT interval in healthy CYP2D6 poor metabolizers**

   **Systematic decrements in QTc between the first and second day of contiguous daily ECG recordings under controlled conditions**
   *PACE* 34:1116-1127; 2011.

4. Millen BA, Campbell GM, Beasley CM
   **Weight changes over time in adults treated with oral or depot formulations of olanzapine: a pooled analysis of 86 clinical trials**

   **Suicidality and risk of suicide – definition, drug safety concerns, and a necessary target for for drug development: a brief report**

   **Suicidality and risk of suicide – definition, drug safety concerns, and a necessary target for for drug development: a consensus statement**

   **Early predictors of weight gain risk during treatment with olanzapine: analysis of pooled data from 58 clinical trials**

8. Beasley CM, Dmitrienko A, Mitchell MI
   **Design and analysis considerations for thorough QT studies employing conventional (10 s, 12-lead)**
ECG recordings


**Fluoxetine and adult suicidality revisited: an updated meta-analysis using expanded data sources from placebo-controlled trials**


10. Tauscher-Wisniewski S, Disch, Plewes J, Ball SG, Beasley CM

**Evaluating suicidality as an adverse event in clinical trials of fluoxetine treatment for indications other than major depressive disorder**


11. Beasley CM, Stauffer VL, Liu-Seifert H, Taylor CC, Dunayevich E, Davis JM,

**All-cause treatment discontinuation in schizophrenia during treatment with olanzapine relative to other antipsychotics: an integrated analysis**


**Treatment-associated suicidal ideation and adverse effects in an open, multicenter trial of fluoxetine for major depressive episodes**


13. Cusin C, Fava M, Amsterdam JD, Quitkin FM, Reimherr FW, Beasley CM, Rosenbaum JF, Perlis RH

**Early symptomatic worsening during treatment with fluoxetine in major depressive disorder: prevalence and implications**


**Effects of Antipsychotic Drugs on I_{in}, I_{Na}, I_{tan}, I_{K1}, and hERG: QT prolongation, structure activity relationship and network analysis**


15. Beasley CM, Sutton VK, Taylor CC, Sethuraman G, Dossenbach M, Naber D

**Is quality of life among minimally symptomatic patients with schizophrenia better following withdrawal or continuation of antipsychotic treatment?**


**Efficacy and safety of oral tadalafil in the treatment of men in Canada with erectile dysfunction: a randomized, double-blind, parallel, placebo-controlled clinical trial**


The combined use of ibutilide as an active control with intensive ECG sampling and signal averaging as a sensitive method to assess the effects of taalafil on the human QT interval

18. Young JM, Feldman RA, Auerbach SM, Kaufman JM, Garcia CS, Shen W, Murphy AM, Beasley CM, Hague JA, Ahuja S
   Tadalafil improved erectile function at 24 and 36 hours after dosing: US trial
   Absence of clinically important HERG channel blockade by three compounds that inhibit phosphodiesterase 5 – sildenafil, tadalafil, and vardenafil
   A multicenter, randomized, double-blind, crossover study to evaluate patient preference between tadalafil and sildenafil
   A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse
   Tadalafil has no detrimental effect on human spermatogenesis or reproductive hormones
23. Carlson CD, Cavazzoni PA, Berg PH, Wei H, Beasley CM, Kane JM
   An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine
24. Lindborg S, Beasley C, Alaka K, Taylor C
   Effects of intramuscular olanzapine vs. haloperidol and placebo on QTc intervals in acutely agitated patients
   When should a trial of fluoxetine for major depression be declared failed?
26. Inada T, Beasley C, Tanaka Y, Walker D
   Extrapyramidal symptom profiles assessed with DIEPSS: comparison with western scales in the clinical double-blind studies of schizophrenic patients treated with either olanzapine or haloperidol

   Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or olanzapine

   Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia
   *Neuropsychopharmacology* 26:494-504; 2002.

29. Brunswick D, Amsterdam J, Fawcett J, Quitkin F, Reimherr, Rosenbaum J, Beasley C
   Fluoxetine and norfluoxetine plasma concentrations during relapse-prevention treatment

   A current review of olanzapine’s safety in the geriatric patient: from pre-clinical pharmacology to clinical data

31. Brunswick D, Amsterdam J, Fawcett J, Quitkin F, Reimherr, Rosenbaum J, Beasley C
   Fluoxetine and norfluoxetine plasma levels after discontinuing fluoxetine therapy

32. Czekalla J, Beasley C, Dellva M, Berg P, Grundy S
   Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis

33. Czekalla J, Kollack-Walker S, Beasley C
   Cardiac Safety Parameters of Olanzapine: comparison with other atypical and typical antipsychotics
Czekalla J, Beasley CM, Ditmann RW, Helsberg K, Kollack-Walker S

**Kardiale verträglichkeit unter nueroleptika: vergleichende übersicht zu Qtc-parametern und assoziierten effekten unter olanzapin und anderen atypischen sowie typischen antipsychotika**

*Nervenheilkunde* 20:194-201; 2001

Perry P, Lund B, Sanger T, Beasley C

**Olanzapine plasma concentrations and clinical response: acute phase results of the North American olanzapine trial**


Beasley C, Koke S, Nilsson M, Gonzales J

**Adverse events and treatment discontinuations in clinical trials of fluoxetine in major depressive disorder: an updated meta-analysis**


Voss S, Sanger T, Beasley C

**Hematologic reference ranges in a population of patients with schizophrenia**


Beasley C, Nilsson M, Koke S, Gonzales J

**Efficacy, adverse events, and treatment discontinuations in fluoxetine clinical studies of major depression: a meta-analysis of the 20-mg/day dose**


**Predictors of Relapse During Fluoxetine Continuation or Maintenance Treatment of Major Depression**


Michelson D, Amsterdam J, Quitkin F, Reimherr F, Rosenbaum J, Zajecka J, Sundell K, Kim Y, Beasley C

**Changes in Weight During a 1-Year Trial of Fluoxetine**


Revicki D, Genduso L, Hamilton S, Ganoczy D, Beasley C

**Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: Quality of life and clinical outcomes of a randomized clinical trial**


Amsterdam J, Garcia-Espana F, Fawcett J, Quitkin F, Reimherr F, Rosenbaum J, Beasley C

**Fluoxetine efficacy in menopausal women with and without estrogen replacement**


Callaghan J, Bergstrom R, Ptak L, Beasley C

**Olanzapine: pharmacokinetic and pharmacodynamic profile**

44. Amsterdam J, Garcia-Espana F, Fawcett J, Quitkin F, Reimherr F, Rosenbaum J, Beasley C
   
   Blood pressure changes during short-term fluoxetine treatment
   

   Beasley C
   
   Changes in adverse events reported by patients during 6 months of fluoxetine therapy
   

   
   Randomized double-blind comparison of the incidence of tardive dyskinesia in patients with 
   schizophrenia during long-term treatment with olanzapine or haloperidol
   

47. Tran P, Tollefson G, Sanger T, Lu Y, Berg P, Beasley C
   
   Olanzapine versus haloperidol in the treatment of schizoaffective disorder. Acute and long-term 
   therapy
   

   
   Olanzapine versus haloperidol treatment in first episode psychosis
   

49. Amsterdam J, Garcia-Espana F, Fawcett J, Quitkin F, Reimherr F, Rosenbaum J, Schweizer E, Beasley C
   
   Efficacy and Safety of Fluoxetine in Treating Bipolar II Major Depressive Episode
   

    P, Sundell K
   
   Optimal length of continuation therapy in depression: a prospective assessment during long-term 
   fluoxetine treatment
   

51. Beasley C
   
   Olanzapine: recent clinical findings and increased patient benefits
   
52. Tollefson G, Sanger T, Beasley C, Tran P
A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia

53. Tran P, Dellva M, Tollefson G, Wentley A, Beasley C
Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses

Safety of abrupt discontinuation of fluoxetine: a randomized, placebo-controlled study

Use of pattern analysis to predict differential relapse of remitted patients with major depression during 1 year of treatment with fluoxetine or placebo
Arch Gen Psychiatry 55:334-343; 1998.

56. Hamilton S, Revicki D, Genduso L, Beasley C
Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind Trial

57. Perry P, Sanger T, Beasley C
Olanzapine plasma concentrations and clinical response in acutely ill schizophrenic patients

58. Dellva M, Tran P, Tollefson G, Wentley A, Beasley C
Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia

59. Goldstein D, Hamilton S, Masica D, Beasley C
Fluoxetine in Medically Stable, Depressed Geriatric Patients: Effects on Weight

60. Crawford A, Beasley C, Tollefson G
The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations

Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and
other psychotic disorders


*Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol*


63. Beasley C, Tollefson G, Tran P

*Safety of olanzapine*


64. Beasley C, Tollefson G, Tran P

*Efficacy of olanzapine: an overview of pivotal clinical trials*


*Fluoxetine in depressed patients on dialysis*


*Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial*


*Fluoxetine and norfluoxetine plasma concentrations in major depression: a multicenter study*


68. Tran P, Dellva M, Tollefson G, Beasley C, Potvin J, Kiesler G

*Extrapyramidal Symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia*


*Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophréniform disorders: results of an international collaborative trial*


70. Beasley C

*Safety of olanzapine*


71. Beasley C

*Efficacy of olanzapine*

   
   **Fluoxetine in depressed patients with renal failure and in depressed patients with normal kidney function**
   
   *Gen Hosp Psychiatry* 18:8-13; 1996.

73. Beasley C, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S
   
   **Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial**
   
   *Psychopharmacology* 124:159-167; 1996.

   
   **Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial**
   
   *Neuropsychopharmacol* 14:111-123; 1996.

75. Tollefson G, Rampey A, Beasley C, Enas G, Potvin J
   
   **Absence of a relationship between adverse events and suicidality during pharmacotherapy for depression**
   

   
   **Evaluation of suicidality during pharmacologic treatment of mood and non-mood disorders**
   

77. Beasley C, Holman S, Potvin J
   
   **Fluoxetine compared with imipramine in the treatment of inpatient depression: a multicenter trial**
   

78. Beasley C, Sayler M, Potvin J
   
   **Fluoxetine versus amitriptyline in the treatment of major depression: a multicenter trial**
   

79. Heiligenstein J, Beasley C, Potvin J
   
   **Fluoxetine not associated with increased aggression in controlled clinical trials**
   

80. Beasley C, Potvin J
   
   **Fluoxetine: activating and sedating effects**
   

81. Bergstrom R, Beasley C, Levy N, Blumenfield M, Lemberger L
   
   **A review of the effects of renal and hepatic disease on the pharmacokinetics, renal tolerance, and their risk-benefit profile of fluoxetine**
   

   
   **Possible monoamine oxidase inhibitor – serotonin uptake inhibitor interaction: fluoxetine clinical**
data and preclinical findings.

83. Goldstein D, Rampey A, Potvin J, Masica D, Beasley C
   Analyses of suicidality in double-blind, placebo-controlled trials of pharmacotherapy for weight reduction

84. Heiligenstien J, Coccaro E, Potvin J, Beasley C, Dornseif B, Masica D
   Fluoxetine not associated with increased violence or aggression in controlled clinical trials

85. Beasley C, Sayler M, Weiss A, Potvin J
   Fluoxetine: activating and sedating effects at multiple fixed doses

86. Wheadon D, Rampey A, Thompson V, Potvin J, Masica D, Beasley C
   Lack of association between fluoxetine and suicidality in bulimia nervosa

   Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression

88. Beasley C, Masica D, Potvin J
   Fluoxetine: a review of receptor and functional effects and their clinical implications

89. Beasley C, Potvin J, Masica D, Wheadon D, Dornseif B, Genduso L
   Fluoxetine: no association with suicidality in obsessive-compulsive disorder
   **Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression**

91. Beasley C, Poltz J, Dornseif B, Bosomworth J, Sayler M
   **Fluoxetine versus trazodone: efficacy and activating-sedating effects**

92. Beasley C, Sayler M, Bosomworth J, Wernicke J
   **High-dose fluoxetine: efficacy and activating-sedating effects in agitated and retarded depression**

93. Usher R, Beasley C, Bosomworth J
   **Efficacy and safety of morning versus evening fluoxetine administration**

   **Fluoxetine in tricyclic refractory major depressive disorder**

95. Beasley C, Bosomworth J, Wernicke J
   **Fluoxetine: relationships among dose, response, adverse events, and plasma concentrations in the treatment of depression**

96. McCombs J, Nichol M, Stimmel G, Sclar D, Beasley C, Gross L
   **The cost of antidepressant drug therapy failure: a study of antidepressant use patterns in a Medicaid population**

97. Beasley C, Magnusson M, Garver D
   **TSH response to TRH and haloperidol response latency in psychoses**

**LETTERS**

1. Beasley C
   **Response (letter).**

2. Perry PJ, Sanger T, Beasley CM
   **Plasma olanzapine and clinical response (Response letter).**

3. Beasley C
   **Response (letter).**
4. Beasley C
   Response (letter).

5. Beasley C
   Response (letter).
   *Neuropsychopharmacol* 16:89-90; 1997.

6. Beasley C
   Fluoxetine-Dopaminergic Interaction Data (letter).

7. Masica D, Beasley C, Kotsanos J, Potvin J
   Trend in suicide rates since fluoxetine introduction (letter).

8. Beasley C
   Reply (letter).

9. Beasley C
   Fluoxetine and suicide (letter).

10. Fuller R, Beasley C
    Fluoxetine: mechanism of action (letter).

11. Beasley C
    Correction to ‘Fluoxetine Overdose: A Case Report’ (letter).
    *J Anal Tox* 14:63; 1990.

**PUBLISHED ABSTRACTS**

   Changes in blood pressure and heart rate associated with atomoxetine treatment in attention-deficit/hyperactivity disorder
   Potential predictive factors for development of treatment-emergent suicidal ideation in the fluoxetine placebo-controlled major depressive disorder database

3. Acharya NV, Rosen AS, Polzer JP, DSouza DN, Perahia DG, Cavazzoni PA, Beasley CM, Baldessarini RJ
   Duloxetine: meta-analysis of suicidal behaviors and thoughts in clinical trials for major depressive disorder

   Does maintenance treatment with atypical antipsychotics worsen quality of life among stable patients with schizophrenia?

   Overall treatment effectiveness as measured by time continuing on antipsychotic therapy

   Prospective evaluation of insulin sensitivity by the hyperinsulinemic, euglycemic clamp in healthy volunteers treated with olanzapine, risperidone or placebo

   Cardiac conduction in females under intramuscular (IM) and oral olanzapine from schizophrenia clinical trials ECGs

8. Tohen M, David RS, Beasley CM, Alaka K
   QT intervals: IM olanzapine treatment in acutely agitated patients
   *European Psychiatry* 17:105; 2002.

9. Beasley CM, Hamilton SH, Dossenbach M
   Relapse prevention with olanzapine

    Cardiac safety profile of olanzapine based on preclinical and clinical ECG data

11. Beasley CM, Hamilton SH, Dossenbach M
    Relapse prevention with olanzapine

12. Tran PV, Basson BR, Kennedy JS, Beasley CM, Bymaster FP, Tollefson GD
    The comparative anti-muscarinic-like side effect profiles of olanzapine and risperidone treatment in
patients with schizophrenia spectrum psychosis

Long term treatment outcomes of highly anxious depressed patients: evidence from a 52-week trial with fluoxetine

A blinded, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol

15. Jones B, Crawford A, Beasley C, Tollefson G
The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentration

What is the differential risk of tardive dyskinesia with the novel antipsychotic olanzapine?

17. Reams S, Sanger T, Beasley C
Olanzapine in the treatment of elderly patients with schizophrenia and related psychotic disorders

18. Tran P, Lu Y, Sanger T, Beasley C, Tollefson G
Olanzapine in the treatment of schizoaffective disorder

The influence of pharmacotherapy on self-directed and externally-directed aggression in schizophrenia
   What is the differential risk of tardive dyskinesia with the atypical antipsychotic olanzapine?

21. Crawford A, Beasley C, Tollefson G
   The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentration

   Olanzapine versus haloperidol: analysis of schizophrenic patients from the multi-center international trial

23. Tran P, Dellva M, Rampey V, Tollefson G, Beasley C
   Long-term continuation therapy with the novel antipsychotic olanzapine: a review of the clinical experience

24. Kuntz A, Tran P, Dellva M, Sanger T, Beasley C, Tollefson G
   Acute phase efficacy and safety of olanzapine: a review

   Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in acute treatment

   Olanzapine in the treatment of schizoaffective disorder
   *European Neuropsychopharmacology* 6:106; 1996.

27. Tollefson G, Sanger T, Beasley C
   The course of primary and secondary negative symptoms in a placebo- and comparator-controlled trial of the atypical antipsychotic olanzapine

   Olanzapine versus placebo, results of the United States double-blind olanzapine trial

29. Quicken FM, Stewart JW, McGrath PJ, Beasley C
   Pattern analysis predicts relapse on fluoxetine and placebo during continuation

   Acute and long-term results of the North American double-blind olanzapine trial
   *Euro Neuropsychopharmacol* 6:59; 1996
   Quality of life outcomes of olanzapine, a new atypical antipsychotic agent

32. Tollefson GD, Beasley CM, Tran PV, Tamura RN, Sanger TM, Wood A, Beuzen JN
   Olanzapine versus haloperidol: results of the multi-center international trial

33. Dittmann R, Beasley C, Geuppert M, Muhlenbacher
   Clinical efficacy and safety of olanzapine: results from a double blind-multinational trial

34. Tran P, Beasley C, Tollefson G, Beuzen J, Holman S, Sanger T, Satterlee W
   Olanzapine: a promising “atypical” antipsychotic agent

35. Saterlee W, Beasley C, Sanger T, Tollefson G
   Additional clinical experiences with olanzapine an “atypical” antipsychotic

36. Satterlee W, Beasley C, Sanger T, Tran P, Paul S, Tollefson G
   Olanzapine a new “atypical” antipsychotic

37. Tran PV, Beasley CM, Tollefson GD, Beuzen JN, Dellva MA, Sanger TM, Paul S
   Acute and long-term results of the North American double-blind olanzapine trial

38. Amsterdam JD, Hornig-Rohan M, Rosenbaum JF, Quitkin FM, Fawcette J, Reimherr FW, Beasley CM
   Fluoxetine and norfluoxetine levels in major depression
   *Biological Psychiatry* 37:606; 1995.

39. Tollefson GD, Beasley CM, Tran PV, Sanger T
   Olanzapine: a novel antipsychotic with broad spectrum profile
   *Biological Psychiatry* 35:746-747; 1994.

40. Wood A, Beasley C, Tollefson G, Tran P
   Efficacy of olanzapine in the positive and negative symptoms of schizophrenia

41. Tran P, Beasley C, Tollefson G, Sanger T, Satterlee W
   Clinical efficacy and safety of olanzapine, a new atypical antipsychotic agent

42. Beasley C, Tollefson G, Moore N, Tye N
   Olanzapine: the new “atypical” antipsychotic agent

   Fluoxetine pharmacokinetics after daily doses of 20 mg fluoxetine in patients with severely impaired renal function


44. Heiligenstein J, Coccaro E, Potvin J, Beasley C, Dornseif B, Masica D

   Fluoxetine not associated with violent behavior in controlled clinical trials


45. Beasley C, Faries D, Sayler M, Potvin J

   Fluoxetine not associated with suicidality in international controlled clinical trials in depression


**GRANT REPORTS**

1. Anderson J, Kline P, Beasley C

   A theory of the acquisition of cognitive skills


2. Anderson J, Kline P, Beasley C

   Complex learning processes


Charles M. Beasley, Jr.

February 18, 2016